Contribution to a book DZNE-2026-01123

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Dementias

 ;  ;  ;  ;  ;  ;

2026
Springer Nature Switzerland Cham

Rosenberg's Atlas of Clinical Neurology / Stüve, MD, PhD, Olaf (Editor) ; Cham : Springer Nature Switzerland, 2026, Chapter 6 ; ISBN: 978-3-032-13039-6 ; doi:10.1007/978-3-032-13040-2 Cham : Springer Nature Switzerland 241-327 () [10.1007/978-3-032-13040-2_6]

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: With aging societies, the incidence and prevalence of dementia are increasing rapidly and will continue to do so worldwide in the next years and decades. It is now possible to diagnose dementia at an early stage using neuropsychological tests and biomarker studies, including imaging (MRI, PET), cerebrospinal fluid analysis, and genetic testing. For Alzheimer’s disease in particular, recent diagnostic advances allow a reliable diagnosis to be made already during a patient’s lifetime. This paves the way for earlier (medical) interventions. In recent years, the first drugs have been approved that intervene causally in the pathogenesis of Alzheimer’s disease rather than just treating its symptoms. As the pathological processes of neurodegenerative brain diseases generally begin years, sometimes decades before the actual clinical onset, a timely treatment with disease-modifying drugs is necessary.With aging societies, the incidence and prevalence of dementia are increasing rapidly and will continue to do so worldwide in the next years and decades. It is now possible to diagnose dementia at an early stage using neuropsychological tests and biomarker studies, including imaging (MRI, PET) cerebrospinal fluid analysis and genetic testing. For Alzheimer’s disease in particular, recent diagnostic advances allow a reliable diagnosis to be made already during a patient’s lifetime. This paves the way for earlier (medical) interventions. In recent years, the first drugs have been approved that intervene causally in the pathogenesis of Alzheimer’s disease rather than just treating its symptoms. As the pathological processes of neurodegenerative brain diseases generally begin years, sometimes decades before the actual clinical onset, a timely treatment with disease-modifying drugs is necessary.


Contributing Institute(s):
  1. Molecular Neuropathology of Neurodegenerative Diseases (AG Neumann)
Research Program(s):
  1. 352 - Disease Mechanisms (POF4-352) (POF4-352)

Click to display QR Code for this record

The record appears in these collections:
Document types > Books > Contribution to a book
Institute Collections > TÜ DZNE > TÜ DZNE-AG Neumann
Documents in Process
Public records
In process

 Record created 2026-10-30, last modified 2026-10-30



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)